196613-57-7

Basic information

• Product Name: 1-Boc-hexahydro-1H-azepin-4-amine
• Synonyms: 4-AMINO-AZEPANE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1H-AZEPINE-1-CARBOXYLIC ACID, 4-AMINOHEXAHYDRO-, 1,1-DIMETHYLETHYL ESTER;1-N-BOC-HEXAHYDRO-1H-AZEPIN-4-AMINE;1-Boc-hexahydro-1H-azepin-4-amine;4-Amino-1-Boc-hexahydro-1H-azepine;tert-Butyl 4-aminoazepane-1-carboxylate;Tert-butyl 4-aminoazepane-1-carboxyalte;1-N-BOC-HEXAHYDRO-1H-AZEPIN-4-
• CAS NO: 196613-57-7
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• EINECS: 200-110-4
• Product Categories: pharmacetical
• Mol File: 196613-57-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 296 ºC
• Flash Point: 133 ºC
• Appearance: /
• Density: 1.020
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.41±0.20(Predicted)
• CAS DataBase Reference: 1-Boc-hexahydro-1H-azepin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-hexahydro-1H-azepin-4-amine(196613-57-7)
• EPA Substance Registry System: 1-Boc-hexahydro-1H-azepin-4-amine(196613-57-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 196613-57-7(Hazardous Substances Data)

Usage

Uses

tert-butyl 4-aminoazepane-1-carboxylate is a useful reagent in the preparation of piperidinyl-nicotinamides used as selective somatostatin receptor subtype 5 antagonists (SSTR5 antagonists).

InChI:InChI=1/C11H22N2O2/c1-11(2,3)15-10(14)13-7-4-5-9(12)6-8-13/h9H,4-8,12H2,1-3H3

Upstream product

• 878630-66-1 tert-butyl 4-(benzylamino)azepane-1-carboxylate 
• 188975-88-4 tert-butyl 4-oxoazepane-1-carboxylate 

Downstream Products

• 878630-97-8 4-(benzyloxycarbonylamino)azepane 
• 1613513-75-9 3,5-Dichlorobenzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)azepane-1-carboxylate 
• 1174020-26-8 tert-butyl (4R)-4-aminoazepane-1-carboxylate 
• 1338719-22-4 (R)-tert-butyl 4-(benzyloxycarbonylamino)azepane-1-carboxylate 
• 1338719-23-5 tert-butyl (S)-4-(((benzyloxy)carbonyl)amino)azepane-1-carboxylate 
• 1338716-37-2 (R)-5-Amino-N-(5-(4-aminoazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(4-methoxy-2-(trifluoromethyl)phenyl)thiazole-4-carboxamide 
• 1338718-86-7 (R)-tert-butyl 4-(5-(4-Cbz-aminoazepan-1-yl)-1-methyl-1H-pyrazol-4-ylcarbamoyl)-2-(5-cyclopropyl-2-fluoro-3-methylphenyl)thiazol-5-ylcarbamate 
• 1338716-22-5 (R)-5-amino-N-(5-(4-aminoazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(5-cyclopropyl-2-fluoro-3-methylphenyl)thiazole-4-carboxamide 
• 1338718-81-2 [(R)-1-(4-{[5-tert-butoxycarbonylamino-2-(2-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-2-methyl-2H-pyrazol-3-yl)-perhydro-azepin-4-yl]-carbamic acid benzyl ester 
• 1338715-89-1 (R)-5-amino-N-(5-(4-aminoazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2-(trifluoromethyl)phenyl)thiazole-4-carboxamide 

Relevant articles and documents

INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

BRADYKININ 1 RECEPTOR ANTAGONISTS

The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.

NOVEL COMPOUNDS

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino -azepines, according to Formula (I). Specifically, the invention is directed to compounds according to Formula (I), wherein: R1 is optionally substituted C3-7cycloalkyl, optionally substituted C3-7cycloalkenyl, optionally substituted Het-C3-7alkyl, optionally substituted Het-C3-7-alkenyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, or optionally substituted indenyl; R2 is H, optionally substituted C1-6alkyl, C3-6cycloalkyl-C0-6alkyl, Ar-C0-6alkyl, or Het-C0-6alkyl; each R3 is independently H, optionally substituted C1-8alkyl, optionally substituted C2-8alkenyl, optionally substituted C2-8alkynyl, Het-C1-6 alkyl, optionally substituted C3-6cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, or optionally substituted C1-C6 alkoxy; R4 is H, or optionally substituted C1-C4 alkyl; R5 is H, optionally substituted C1-8alkyl, optionally substituted C2-8alkenyl, optionally substituted C2-8alkynyl, optionally substituted C3-6cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R6 is H or C1-6alkyl; and X is SO2, CO, CH2, or CONH, and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof.